Lékové interakce – rizika u pacientů s polypragmazií
Authors:
Karolína Russ 1; Tereza Vaňková 1,2
Authors‘ workplace:
Oddělení klinické farmacie, Nemocnice AGEL Ostrava-Vítkovice
1; Oddělení klinické farmacie, Nemocnice AGEL Nový Jičín
2
Published in:
Čas. Lék. čes. 2024; 163: 9-17
Category:
Review Articles
Overview
Polypharmacy, a phenomenon of today’s medicine, brings a great risk of drug interactions. Some of them can lead to serious side effects or treatment failure, knowledge in this field is dramatically developing. Pharmacokinetic drug interactions can occur not only when drugs are metabolized by the cytochrome P450 isoenzyme system, but also at the level of transporters, a number of which have already been described. In order to assess their clinical significance, it is necessary to orient oneself in the pharmacodynamics and pharmacokinetics of drugs, but also to consider other factors that will influence the impact of drug interactions. The physician should be familiar with commonly prescribed drugs with a high interaction potential, be aware of strong inducers and inhibitors of CYP450, as well as the possible influence of genetic polymorphism of some of its isoforms. However, one should not rely on the interpretation of drug interactions only using available interaction databases. No software is yet capable of evaluating interactions comprehensively and in the context of a specific patient, their health status and comorbidities. Also, the information available from clinical studies and observations needs to be properly understood and translated into real practice. Nowadays, it is a great advantage a doctor can consult with a clinical pharmacist or pharmacologist on the issue of drug interactions in a specific patient. This article summarizes the issue of drug interactions, focusing on the less intuitive ones, with examples from practice.
Keywords:
drug interactions, polypharmacy, inhibitor, inducer, substrate, transport system, clinical pharmacist
Sources
- Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17: 1–10.
- Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf 2016; 39: 109–116.
- Marengoni A, Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. Brit Med J 2015; 350: h1059.
- Květina J, Grundmann M. Farmakologické interakce. Klin Farmakol Farm 2003; 1: 17–21.
- Suchopár J, Prokeš M, Suchopár Š. Lékové interakce. Obecné aspekty lékových interakcí (svazek 1a, 1b). DrugAgency, Praha, 2023.
- ASHP Injectable Drug Information. ASHP, 2023. Dostupné na: www.ashp.org/products-and-services/injectables
- Stockley’s Interactions Checker. Pharmaceutical Press, 2024 Mar 12. Dostupné na: www.pharmaceuticalpress.com/products/stockleys-interactions-checker
- Lakehal F, Wurden CJ, Kalhorn TF, Levy RH. Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. Epilepsy Res 2002; 52: 79–83.
- Di Gennaro L, Lancellotti S, De Cristofaro R, De Candia E. Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy. J Thromb Thrombolysis 2019; 48: 528–531.
- Mannheimer B, Andersson ML, Järnbert-Pettersson H, Lindh JD. The effect of carbamazepine on warfarin anticoagulation: a register‐based nationwide cohort study involving the Swedish population. J Thromb Haemost 2016; 14: 765–771.
- Breithaupt MH, Krohmer E, Taylor L et al. Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers. Br J Clin Pharmacol 2023; 89: 2458–2464.
- Khan S, Jones S, Preston CL. Theophylline interactions. Pharm J 2014; 293: 7818.
- Zhao M, Ma J, Li M et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci 2021; 22: 12808.
- Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets 2018; 19: 38–54.
- Pechandová K, Buzková H, Slanař O, Perlík F. Efluxní transmembránový transportér – P-glykoprotein. Klin Biochem Metab 2006; 4: 196–201.
- Thiebaut F, Tsuruo T, Hamada H et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735–7738.
- Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42: 59–98.
- Drug development and drug interactions: table of substrates, inhibitors and inducers. FDA, 2023 May 6. Dostupné na: www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
- SPC Pradaxa. Dostupné na: https://prehledy.sukl.cz/prehled_leciv.html#/detail-reg/0029326
- Delavenne X, Ollier E, Basset T et al. A semi‐mechanistic absorption model to evaluate drug–drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 2013; 76: 107–113.
- Gouin‐Thibault I, Delavenne X, Blanchard A et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost 2017; 15: 273–283.
- Hill K, Sucha E, Rhodes E et al. Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants. JAMA Intern Med 2020; 180: 1052–1060.
- SPC Tarceva. Dostupné na: https://prehledy.sukl.cz/prehled_leciv.html#/detail-reg/0025419
- SPC Lynparza. Dostupné na: https://prehledy.sukl.cz/prehled_leciv.html#/detail-reg/0222935
- Lankheet NAG, Kloth JSL, Gadellaa-van-Hooijdonk CGM et al. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer 2014; 110: 2441–2449.
- Musil D. Akutní infekce, žilní trombóza a doporučená tromboprofylaxe. Vnitř Lék 2020; 66: 17–23.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
![Issue 1–2](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image/f3f68368bd5d82b25a3056e3f41d2600.jpg)
Most read in this issue
- Polypragmazie a jak jí předcházet
- Akatizie – častý, ale obtížně rozpoznatelný nežádoucí účinek?
- Geografie zdraví – průzkum prostorových nerovností ve zdraví v Česku
- Je obezita a malnutrice u geriatrických pacientů problémem z hlediska dávkování analgetik?